| Title: |
Sequential Use of Sorafenib and Regorafenib in Hepatocellular Cancer Recurrence After Liver Transplantation: Treatment Strategies and Outcomes |
| Authors: |
Mehmet Fatih Ozbay; Hakan Harputluoglu; Mustafa Karaca; Omer Tekin; Mehmet Ali Nahit Şendur; Muhammed Ali Kaplan; Berksoy Sahin; Caglayan Geredeli; Fatih Teker; Deniz Tural; Sezer Saglam; Timuçin Çil; Ahmet Bilici; Cihan Erol; Ziya Kalkan; Ertugrul Bayram; Oguzhan Selvi; İlkay Gültürk; Sema Sezgin Göksu; Ali Murat Tatlı |
| Source: |
Cancers ; Volume 16 ; Issue 22 ; Pages: 3880 |
| Publisher Information: |
Multidisciplinary Digital Publishing Institute |
| Publication Year: |
2024 |
| Collection: |
MDPI Open Access Publishing |
| Subject Terms: |
hepatocellular carcinoma (HCC); liver transplantation; sorafenib; regorafenib; post-transplant recurrence |
| Description: |
Background and Aims: During liver transplantation, hepatocellular carcinoma (HCC) recurrence remains a critical challenge for patient survival. Targeted therapies, such as sorafenib and regorafenib, have been utilized to manage relapsed HCC in this unique setting. This study aimed to assess the efficacy of Sorafenib and Regorafenib in patients with HCC who experienced recurrence after liver transplantation. We focused on survival outcomes, treatment responses, and the management of side effects in this patient group. Methods: We conducted a retrospective analysis of 73 patients who experienced HCC recurrence post-liver transplantation between 2012 and 2022 across 11 oncology centers in Turkey. Patients were categorized according to Child–Pugh classification and treated with sorafenib as first-line therapy and Regorafenib in case of progression. Survival rates were analyzed using the Kaplan–Meier method, and risk factors were evaluated using Cox regression analysis. Results: Of the 73 patients included in the study, 62 were male (84.9%), and 11 were female (15.1%), with a mean age of 61.5 ± 10.9 years. All patients received sorafenib as first-line treatment. Among patients who experienced progression with sorafenib or discontinued treatment due to toxicity, 45.2% (n = 33) continued treatment with regorafenib. The median progression-free survival (PFS1) time with sorafenib was 5.6 months, and the one-year survival rate was 24.3%. The median progression-free survival (PFS2) time with regorafenib, which was administered as second-line treatment, was also calculated as 5.9 months. Overall survival (OS) duration was determined as 35.9 months. The most common side effects associated with both drugs included fatigue, hand and foot syndrome, and hypertension. Significantly better survival outcomes were shown in the Child–Pugh A group compared to other patients. Conclusions: These results suggest that Sorafenib and Regorafenib treatments offer a survival advantage in patients with relapsed HCC post-transplantation. ... |
| Document Type: |
text |
| File Description: |
application/pdf |
| Language: |
English |
| Relation: |
Cancer Therapy; https://dx.doi.org/10.3390/cancers16223880 |
| DOI: |
10.3390/cancers16223880 |
| Availability: |
https://doi.org/10.3390/cancers16223880 |
| Rights: |
https://creativecommons.org/licenses/by/4.0/ |
| Accession Number: |
edsbas.4D6A7D35 |
| Database: |
BASE |